Gongqingcheng Shengbang Yinghao Investment Partnership (Limited Partnership) completed the acquisition of 20.99% stake in Pacific Shuanglin Bio-pharmacy Co., LTD from Hangzhou Zhemintou Tianhong Investment Partnership Enterprise (LP) and Zhejiang Private Enterprise United Investment Co., Ltd.
May 22, 2023
Share
Gongqingcheng Shengbang Yinghao Investment Partnership (Limited Partnership) signed a share transfer agreement to acquire 20.99% stake in Pacific Shuanglin Bio-pharmacy Co., LTD (SZSE:000403) from Hangzhou Zhemintou Tianhong Investment Partnership Enterprise (LP) and Zhejiang Private Enterprise United Investment Co., Ltd. for approximately CNY 3.84 billion on March 20, 2023. The total price of the share transfer was CNY 3.84 billon, of which the share transfer price paid to Zhejiang Private Enterprise United Investment was 482.2 millon, and the share transfer price paid to Hangzhou Zhemintou Tianhong Investment Partnership Enterprise (LP) price is 3.36billion. Payment will be paid in three installments.
Gongqingcheng Shengbang Yinghao Investment Partnership (Limited Partnership) completed the acquisition of 20.99% stake in Pacific Shuanglin Bio-pharmacy Co., LTD (SZSE:000403) from Hangzhou Zhemintou Tianhong Investment Partnership Enterprise (LP) and Zhejiang Private Enterprise United Investment Co., Ltd. on May 23, 2023.
Pacific Shuanglin Bio pharmacy Co Ltd, formerly Southern Shuanglin Bio-pharmacy Co Ltd, formerly Zhenxing Biopharmaceutical & Chemical Co., Ltd., is a China-based company mainly engaged in the research, development, production and sales of blood products. The Company's main products are human albumin, intravenous immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin and rabies immunoglobulin. The Company mainly operates its business in the domestic market.
PACIFIC SHUANGLIN BIO-PHARMACY CO., LTD 
